Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Positive
EXEL
Exelixis IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$14.62B
P/E Ratio
18.56
EPS
$3.18
Beta
0.42
52W High
$59.72
52W Low
$33.76
50-Day MA
$54.93
200-Day MA
$47.57
Dividend Yield
—
Profit Margin
35.30%
Forward P/E
13.77
PEG Ratio
2.27
About Exelixis Inc
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Fundamentals
| Revenue (TTM) | $2.44B |
| Gross Profit (TTM) | $2.35B |
| EBITDA | $1.02B |
| Operating Margin | 39.50% |
| Return on Equity | 44.40% |
| Return on Assets | 24.00% |
| Revenue/Share (TTM) | $9.33 |
| Book Value | $7.41 |
| Price-to-Book | 7.95 |
| Price-to-Sales (TTM) | 6.00 |
| EV/Revenue | 5.74 |
| EV/EBITDA | 13.70 |
| Quarterly Earnings Growth (YoY) | 26.20% |
| Quarterly Revenue Growth (YoY) | 10.60% |
| Shares Outstanding | $247.78M |
| Float | $213.60M |
| % Insiders | 1.84% |
| % Institutions | 107.08% |
Historical Volatility
HV 10-Day
33.29%
HV 20-Day
31.98%
HV 30-Day
43.32%
HV 60-Day
34.50%
HV Rank
74.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($53.69 target)
1
Strong Buy6
Buy11
Hold1
Strong SellLatest News
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research9/3/2026Positive
Cancer Stock Breaks Out To Highs; Key FDA Action On Watch
Cancer treatment name Exelixis is attempting to clear a flat base with a 57.57 pivot.
Investors Business Daily9/2/2026Positive
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data
Exelixis is downgraded from "Strong Buy" to "Hold" due to lowered 2026 revenue guidance and mixed clinical trial outcomes. Zanzalintinib + TECENTRIQ achieved overall survival benefit in mCRC, but missed the non-liver metastases subgroup endpoint; FDA PDUFA date set for December 3, 2026. Q2 2026 revenues rose to $628.7M, but future sales growth is uncertain and full-year guidance was cut to $2.500–$2.550B.
Seeking Alpha9/1/2026Positive
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District of Delaware in Exelixis' favor. The appellate court upheld the District Court's decision that three patents covering.
Business Wire8/31/2026Neutral
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research8/20/2026Positive
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
PRNewsWire8/19/2026Neutral
Here's Why Exelixis (EXEL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research8/18/2026Positive
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating.
PRNewsWire8/17/2026Neutral
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law.
Business Wire8/16/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EXEL and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026